Drug Trial Radar · NCT06173869
A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in China
Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
301
Actual
Start
Mar 29, 2024
Primary completion
May 31, 2025
Study completion May 31, 2025
Sponsor
- Lead sponsor
- Ferring PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Dec 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 20 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3b clinical trial with follitropin delta (FE 999049) and Gonal-F. The trial is a randomised, controlled, assessor-blind, parallel groups, multicentre trial comparing the ovarian response of a starting dose of either 10mg or 15 mg follitropin delta to a starting dose of either 150 IU or 225 IU Gonal-F in a long GnRH agonist protocol in women undergoing an assisted reproductive technology programme in China.
Conditions
- Infertility, Female
Interventions
FE 999049Drug
FE 999049 was administered as single daily subcutaneous injections at a starting dose of either 10 or 15 µg daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 5 µg, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 5 µg, and the maximum daily dose was 20 µg. Participants could be treated for a maximum of 20 days.
GONAL-FDrug
GONAL-F was administered as single daily subcutaneous injections at a starting dose of either 150 or 225 IU daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 75 IU, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 75 IU, and the maximum daily dose was 300 IU. Participants could be treated for a maximum of 20 days. Coasting was not allowed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Oocytes RetrievedTime frame: On day of oocyte retrieval (up to 22 days after start of stimulation)
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Ferring Investigational Site
Shushan, Anhui, China
Ferring Investigational Site
Yuzhong, Chongqing Municipality, China
Ferring Investigational Site
Guangzhou, Guandong, China
Ferring Investigational Site
Guangzhou, Guangdong, China
Ferring Investigational Site
Zhengzhou, Henan, China
Ferring Investigational Site
Nanchang, Jiangxi, China
Ferring Investigational Site
Shengyang, Liaoling, China
Ferring Investigational Site
Shanghai, Shanghai Municipality, China
Ferring Investigational Site
Chengdu, Sichuang, China
Ferring Investigational Site
Tianjin, Tianjin Municipality, China
Ferring Investigational Site
Xiaobailou, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.